Blood test to monitor treatment response in triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer (TNBC), which means your cancer cells don't have receptors for estrogen, progesterone, or too much HER2.
- Your breast cancer is at an early stage (stage I, II, or III) and you are about to start chemotherapy before surgery (called neoadjuvant treatment).
- You are at least 18 years old.
- You are willing to give blood samples before and during your treatment.
- You have a tissue sample (biopsy) from your tumor available for testing.
- You have not started any treatment for this breast cancer yet (like chemotherapy or other drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This study is testing a way to use a simple blood test during chemotherapy to see how well the treatment is working in certain breast cancers. The goal is to make sure you get the best treatment for your tumor type.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial studies a simple blood test that may predict how well your body responds to chemotherapy plus immunotherapy before surgery for triple-negative breast cancer. The goal is to use these clues to personalize your treatment in the future.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
Hear when a new Minimal Residual Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.